GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dynavax Technologies Corp (NAS:DVAX) » Definitions » Piotroski F-Score
中文

Dynavax Technologies (Dynavax Technologies) Piotroski F-Score

: 5 (As of Today)
View and export this data going back to 2004. Start your Free Trial

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dynavax Technologies has an F-score of 5 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Dynavax Technologies's Piotroski F-Score or its related term are showing as below:

DVAX' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 4   Max: 7
Current: 5

During the past 13 years, the highest Piotroski F-Score of Dynavax Technologies was 7. The lowest was 3. And the median was 4.


Dynavax Technologies Piotroski F-Score Historical Data

The historical data trend for Dynavax Technologies's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dynavax Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 3.00 6.00 7.00 5.00

Dynavax Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 6.00 5.00 5.00

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dynavax Technologies Piotroski F-Score Distribution

For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Dynavax Technologies's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -24.332 + 3.431 + 14.293 + 0.219 = $-6.4 Mil.
Cash Flow from Operations was 27.622 + 28.046 + 31.129 + 13.766 = $100.6 Mil.
Revenue was 46.925 + 60.249 + 69.514 + 55.596 = $232.3 Mil.
Gross Profit was 32.213 + 46.712 + 56.285 + 46.907 = $182.1 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(985.85 + 969.922 + 936.432 + 972.933 + 997.096) / 5 = $972.4466 Mil.
Total Assets at the begining of this year (Dec22) was $985.9 Mil.
Long-Term Debt & Capital Lease Obligation was $252.4 Mil.
Total Current Assets was $859.1 Mil.
Total Current Liabilities was $62.2 Mil.
Net Income was 32.859 + 128.755 + 63.809 + 67.733 = $293.2 Mil.

Revenue was 113.992 + 256.464 + 167.735 + 184.492 = $722.7 Mil.
Gross Profit was 74.03 + 173.095 + 106.401 + 107.004 = $460.5 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1039.246 + 1008.975 + 1022.999 + 999.337 + 985.85) / 5 = $1011.2814 Mil.
Total Assets at the begining of last year (Dec21) was $1,039.2 Mil.
Long-Term Debt & Capital Lease Obligation was $254.4 Mil.
Total Current Assets was $917.0 Mil.
Total Current Liabilities was $150.1 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dynavax Technologies's current Net Income (TTM) was -6.4. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Dynavax Technologies's current Cash Flow from Operations (TTM) was 100.6. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-6.389/985.85
=-0.0064807

ROA (Last Year)=Net Income/Total Assets (Dec21)
=293.156/1039.246
=0.28208528

Dynavax Technologies's return on assets of this year was -0.0064807. Dynavax Technologies's return on assets of last year was 0.28208528. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Dynavax Technologies's current Net Income (TTM) was -6.4. Dynavax Technologies's current Cash Flow from Operations (TTM) was 100.6. ==> 100.6 > -6.4 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=252.418/972.4466
=0.25957004

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=254.379/1011.2814
=0.25154126

Dynavax Technologies's gearing of this year was 0.25957004. Dynavax Technologies's gearing of last year was 0.25154126. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=859.12/62.195
=13.81332905

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=916.985/150.074
=6.11021896

Dynavax Technologies's current ratio of this year was 13.81332905. Dynavax Technologies's current ratio of last year was 6.11021896. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Dynavax Technologies's number of shares in issue this year was 129.387. Dynavax Technologies's number of shares in issue last year was 151.889. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=182.117/232.284
=0.78402731

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=460.53/722.683
=0.63725036

Dynavax Technologies's gross margin of this year was 0.78402731. Dynavax Technologies's gross margin of last year was 0.63725036. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=232.284/985.85
=0.23561799

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=722.683/1039.246
=0.69539166

Dynavax Technologies's asset turnover of this year was 0.23561799. Dynavax Technologies's asset turnover of last year was 0.69539166. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+0+1+0+1+1+1+0
=5

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Dynavax Technologies has an F-score of 5 indicating the company's financial situation is typical for a stable company.

Dynavax Technologies  (NAS:DVAX) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Dynavax Technologies Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Dynavax Technologies's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Dynavax Technologies (Dynavax Technologies) Business Description

Traded in Other Exchanges
Address
2100 Powell Street, Suite 900, Emeryville, CA, USA, 94608
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Executives
Robert Janssen officer: Chief Medical Officer and VP C/O DYNAVAX TECHNOLOGIES, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
David F Novack officer: Senior Vice President 39 YORKSHIRE DR, OAKLAND CA 94618
Hack Andrew A. F. director 300 THIRD STREET, FIRST FLOOR, CAMBRIDGE MA 02142
Justin Burgess officer: Principal Accounting Officer C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 1900, EMERYVILLE CA 94608
Ryan Spencer officer: Co-President and Senior VP C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710-2753
Francis Cano director 11 ACORN LANE, LOS ALTOS CA 94022
Elaine D Sun director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Scott Dunseth Myers director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Macdonald officer: SVP and CFO 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Peter R. Paradiso director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Julia Marie Eastland director C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Brent Macgregor director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2100 POWELL STREET, SUITE 900, EMERYVILLE CA 94608
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Robert Coffman officer: Chief Science Officer and VP C/O DYNAVAX TECHNOLOGIES CORP, 2929 SEVENTH ST STE 100, BERKELEY CA 94710
Michael S Ostrach officer: VP, CBO, and General Counsel 1300 SEAPORT BOULEVARD, REDWOOD CITY CA 94063